본문 바로가기
KERD
논문KCI 등재

만성 두통 환자에서 Botulinum Toxin Type A 치료

Botulinum Toxin Type A Therapy in Chronic Headache Patients

김은성|문영은|김시현|문동언
대한통증학회 (The Korean Pain Society)|2005.06|The Korean Journal of Pain|제18권 제1호|pp. 29-33

2

조회

0

다운로드

1

인용

0

참고문헌

초록

Abstract

Background: Chronic headache (CH) constitutes a significant public health problem, impacting on both the individual sufferer and society. Patients with CH, unresponsive to drug therapy or nerve block, suffer considerable disability due to the frequency and severity of attacks; therefore, they should be considered for novel therapy. Botulinum toxin type A (BoNT-A) has shown significant promise in the management of CH. In this paper, we review recent evidence on the efficacy of BoNT-A, and also report our experience with this treatment in CH patients. Methods: BoNT-A was used to treat 69 CH patients, including 47 in a chronic migraine group and 22 in a non-migraine CH group, who showed therapy-resistance to palliative drug or nerve block. We investigated the demography, dosage and site of BoNT-A injection, and used a visual analogue scale (VAS) for pain and the degree of satisfaction. The data were analyzed using t-tests and a Friedman repeated measures analysis of variance on ranks. Results: Significant decreases in the VAS for pain were found in both the chronic migraine and non-migraine CH groups, from 2, 4 and 12 weeks and from 4 and 12 weeks, respectively, after BoNT-A administration (P ＜ 0.05). The chronic migraine group showed significantly lower VAS scores for pain than the non-migraine CH group from 2, 4 and 12 weeks after the BoNT-A administration (P ＜ 0.05). Twenty eight patients (59.2%) in the chronic migraine group and eight (36.4%) in the non-migraine CH were satisfied with the BoNT-A treatment. Conclusions: This clinical study revealed that the use of BoNT-A demonstrated efficacy for CH patients resistant to drug therapy or nerve block. Moreover, BoNT-A proved itself more effective in the chronic migraine than non-migraine CH group.

참고문헌 (26)

  1. "The use of botulinum toxins in the management of pain and headache", 1, pp.215~35 (2001)
  2. "Pharmacologic weakening of the extraocular muscles", 12, pp.924~ (1973)
  3. "The current use of botulinum toxin", 7, pp.389~94 (2000)
  4. "Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes", 91, pp.195~99 (2001)
  5. "The use of botulinum toxin for the treatment of chronic facial pain", 3, pp.21~7 (2002)
  6. "Botulinum toxin type A therapy in chronic pain disorders", 84, pp.~73 (2003)
  7. "Epidemiology of chronic daily headache in the general population", 39, pp.190~6 (1999)
  8. "Prevalence and burden of migraine in the United States:data from the American Migraine Study II", 41, pp.646~57 (2001)
  9. "Therapeutic effect of the patients with chronic migraine in pain clinic", 17, pp.146~52 (2004)
  10. "Basic mechanisms in vascular headache", 8, pp.801~15 (1990)
  11. "Botulinum toxin : chemistry, pharmacology, toxicity and immunology", 20(6), pp.146~168 (1997)
  12. "Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection", 19, pp.488~95 (1996)
  13. "Pharmacology and immunology of botulinum toxin serotypes", 248(1), pp.3~10 (2001)
  14. "Basic aspects of botulinum toxin:physiology and pharmacology of therapeutic botulinum neurotoxins", 30, pp.107~16 (2002)
  15. "An association between migraine and cutaneous allodynia", 47, pp.614~24 (2000)
  16. "Expression of neurotransmitter genes in rat spinal motorneurons after chemodenervation with botulinum toxin", 78, pp.469~79 (1997)
  17. "Subcutaneous administration of botulinum toxin A reduces formalin induced pain", 107, pp.125~33 (2004)
  18. "Peripheral and central sensitization during migraine", 15(3), pp.28~35 (2000)
  19. "Evidence for antinociceptive activity of botulinum toxin type A in pain management", 43(1), pp.9~15 (2003)
  20. "Botulinum toxin type A for treatment of migraine headaches:an open-label study", 123, pp.669~76 (2000)
  21. "Botulinum toxin type A as a migraine preventive treatment", 40, pp.445~50 (2000)
  22. "Botox for migraine", 20, pp.421~ (2000)
  23. "Efficacy and safety of botulinum toxin type A in the prophylactic treatment of migraine", 42, pp.~452 (2002)
  24. "Treatment of headache with botulinum toxin A- a review according to evidence-based medicine criteria", 22, pp.699~710 (2002)
  25. "Effect of botulinum toxin A injections in the treatment of chronic tension-type headache", 41, pp.658~64 (2001)
  26. "Treatment of frontal tension headaches with botulinum toxin A", 21, pp.486~91 (2001)

관련 논문AI추천

만성 편두통에서의 보톡스 치료류상효대한신경과학회 · 대한신경과학회지2024 · 제42권 제1호통증클리닉에서 만성편두통 환자의 치료 효과문동언, 박종민, 양소영, 윤재원대한통증학회 · The Korean Journal of Pain2004 · 제17권 제2호Prolonged Effect of OnabotulinumtoxinA on Chronic Migraine in 87 Koreans김만호, 변정익, 심지영대한신경과학회 · Journal of Clinical Neurology2017 · 제13권 제1호보툴리늄 A형 독소를 이용한 경부 근근막 증후군의 치료이경진대한통증학회 · The Korean Journal of Pain2003 · 제16권 제2호만성 편두통과 삽화성 편두통 환자의 삶의 질 비교도진국, 박재용, 안호기, 이동국, 한창현대한신경과학회 · 대한신경과학회지2007 · 제25권 제3호만성편두통 치료를 위한 측두 부위의 보툴리눔 독소 주사 자입점 제시김성택, 김영건, 배정희대한턱관절교합학회 · 구강회복응용과학지2017 · 제33권 제1호

이 간행물의 다른 논문 (20건)

Antinociceptive Effects of Intrathecal Metabotropic Glutamate Receptor Compounds and Morphine in Rats정성태, 정창영, 정성수, 윤명하, Hong Beom Bae, 최정일, Chang Mo Kim, Seok Jai Kim, Hyung Kon Leepp. 1-9방사열 자극실험쥐에서 Ketorolac과 Morphine의 병용투여 효과최동훈, 윤덕미, 이윤우, 노장호pp. 10-14노인에서 경막외강에 3회 분할 투여된 Triamcinolone 60 mg이 혈중 포도당, ACTH와 Cortisol에 미치는 영향정영주, 민순, 고지은, 이헌근pp. 15-18경막외 카테터 피하매몰법을 이용한 지속적 모르핀 투여에 의한 말기암 환자의 통증관리김경한, 류시정, 김준영, 최형규, 김두식, 장태호, 김세환pp. 19-22요천추부 신경근병증의 치료를 위한 경추간공 경막외 스테로이드 주입과 요추 및 미추 경막외 스테로이드 주입의 비교이원형, 정선섭pp. 23-28
원문 보기